Bridgewater Associates LP Sells 12,970 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Bridgewater Associates LP reduced its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 72.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,959 shares of the company's stock after selling 12,970 shares during the period. Bridgewater Associates LP's holdings in Omnicell were worth $221,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in OMCL. Vanguard Group Inc. lifted its position in shares of Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock worth $247,628,000 after purchasing an additional 28,573 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Omnicell by 32.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after purchasing an additional 377,883 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after buying an additional 699,925 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock worth $48,176,000 after purchasing an additional 2,877 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Omnicell by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company's stock valued at $27,431,000 after acquiring an additional 21,157 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Omnicell Stock Performance

NASDAQ:OMCL traded down $0.25 during mid-day trading on Friday, hitting $30.96. The stock had a trading volume of 454,205 shares, compared to its average volume of 536,494. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company's 50 day simple moving average is $34.32 and its 200 day simple moving average is $40.87. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 114.67, a PEG ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analysts Set New Price Targets

OMCL has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Benchmark reaffirmed a "buy" rating and issued a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Wells Fargo & Company cut their target price on Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of "Hold" and an average price target of $50.67.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.